argenx SE (XBRU:ARGX) Other Current Liabilities : €87 Mil (As of Dec. 2023)

View and export this data going back to 2014. Start your Free Trial

What is argenx SE Other Current Liabilities?

argenx SE's other current liabilities for the quarter that ended in Dec. 2023 was €87 Mil.

argenx SE's quarterly other current liabilities declined from Jun. 2023 (€65 Mil) to Sep. 2023 (€0 Mil) but then increased from Sep. 2023 (€0 Mil) to Dec. 2023 (€87 Mil).

argenx SE's annual other current liabilities increased from Dec. 2021 (€74 Mil) to Dec. 2022 (€80 Mil) and increased from Dec. 2022 (€80 Mil) to Dec. 2023 (€87 Mil).

argenx SE Other Current Liabilities Historical Data

The historical data trend for argenx SE's Other Current Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

argenx SE Other Current Liabilities Chart

argenx SE Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Other Current Liabilities

Get a 7-Day Free Trial

argenx SE Quarterly Data
	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Jun20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Other Current Liabilities	Get a 7-Day Free Trial															-	-	-	-	-

argenx SE Other Current Liabilities Calculation

The liability a company needs to pay in the next 12 months, but not assigned to Accounts Payable or Debt. For instance, Wal-Mart (WMT) has accrued wages, salaries, valuation, bonuses, insurance liabilities, accrued tax etc. These are all included in other current liabilities.

argenx SE Other Current Liabilities Related Terms

Thank you for viewing the detailed overview of argenx SE's Other Current Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

argenx SE (XBRU:ARGX) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » argenx SE (XBRU:ARGX) » Definitions » Other Current Liabilities

Comparable Companies

Traded in Other Exchanges

ARGX:USA ARGX:Mexico ARGXb:UK 0QW0:UK 1AEA:Germany 1AE:Germany 1AE:Germany A1RG34:Brazil ARGX:Austria

Address

Laarderhoogtweg 25, Amsterdam, NH, NLD, 1101EB

Website

https://www.argenx.com

Argenx is a Dutch company focused on using its antibody engineering technology to treat rare autoimmune diseases. Vyvgart (efgartigimod) was approved in the U.S. in December 2021 as a treatment for generalized myasthenia gravis, followed by approvals in Europe and Japan in 2022.